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Deregulated cathepsin proteolysis occurs across
numerous cancers, but in vivo substrates mediating
tumorigenesis remain ill-defined. Applying 8-plex
iTRAQ terminal amine isotopic labeling of substrates
(TAILS), a systems-level N-terminome degradomics
approach, we identified cathepsin B, H, L, S, and
Z in vivo substrates and cleavage sites with the use
of six different cathepsin knockout genotypes in
the Rip1-Tag2 mouse model of pancreatic neuroen-
docrine tumorigenesis. Among 1,935 proteins and
1,114 N termini identified by TAILS, stable proteo-
lytic products were identified in wild-type tumors
compared with one or more different cathepsin
knockouts (17%–44% of 139 cleavages). This sug-
gests a lack of compensation at the substrate level
by other cathepsins. The majority of neo-N termini
(56%–83%) forall cathepsinswasconsistentwithpro-
tein degradation. We validated substrates, including
the glycolytic enzyme pyruvate kinaseM2 associated
with the Warburg effect, the ER chaperone GRP78,
and the oncoprotein prothymosin-alpha. Thus, the
identification of cathepsin substrates in tumorigen-
esis improves the understanding of cathepsin func-
tions in normal physiology and cancer.INTRODUCTION
Pancreatic neuroendocrine tumors (PanNETs) are the second
most common pancreatic neoplasms, and are clinically chal-1762 Cell Reports 16, 1762–1773, August 9, 2016 ª 2016 The Author
This is an open access article under the CC BY-NC-ND license (http://lenging, in part because of considerable disease heterogeneity
and a limited understanding of the molecular basis of the pathol-
ogy (Milan and Yeo, 2012). In PanNETs, as well as other tumors,
deregulated proteolysis is a key feature (Affara et al., 2009; Over-
all and Kleifeld, 2006; Sevenich and Joyce, 2014). Altered
expression, activity, and localization of cysteine cathepsin prote-
ases occur in human and murine tumors and positively correlate
with prognosis and therapeutic response. Pharmacological inhi-
bition or genetic ablation of cathepsins generally impairs cancer
progression, implicating cathepsins in disease etiology (Mo-
hamed and Sloane, 2006; Olson and Joyce, 2015).
Cysteine cathepsins are a protease family normally found in
lysosomal/endolysosomal compartments where they degrade
proteins under acidic conditions, thereby playing an important
role in terminal protein degradation, prohormone maturation
and antigen processing and presentation (Turk et al., 2012).
There are eleven cysteine cathepsins (Cts) in humans (B, C, H,
F, K, L, O, S, L2/V,W, and X/Z) comprising endopeptidases, ami-
nopeptidases, and carboxypeptidases. In tumors, upregulation
of cathepsin activity is expected to provide a survival advantage
to the cancer cells by supporting their higher proliferation rates
and increased metabolism, suggesting lysosome-targeting re-
agents as anticancer drugs (Kallunki et al., 2013). In addition,
cathepsins are secreted into the tumor microenvironment, with
tumor-associated macrophages being a significant source that
support tumorigenesis (Gocheva et al., 2006; Joyce et al.,
2004; Olson and Joyce, 2015; Sevenich et al., 2014; Sobotic
et al., 2015; Wang et al., 2006). Secreted cathepsins were origi-
nally thought to promote tumor growth solely by degrading
extracellular matrix (ECM), but cathepsins B, K, L and S have
additionally been shown to activate other proteases and chemo-
kines at neutral pH (Hasan et al., 2006; Repnik et al., 2015),
degrade cell junction molecules and shed ectodomains of mem-
brane proteins (Gocheva et al., 2006; Olson and Joyce, 2015;(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Sevenich et al., 2014; Sobotic et al., 2015; Wang et al., 2006),
supporting multiple roles in tumorigenesis.
Intriguingly, mechanistic studies using different animal models
of cancer show that the functional outcome of high protease ac-
tivity is not always pro-tumorigenic (Overall and Kleifeld, 2006).
For cathepsins this depends on the cancer model, the organ
site, the specific cathepsin, and the cellular source of cathepsin
activity (Olson and Joyce, 2015). For instance, CtsB promotes
cancer progression in animal models of pancreatic (Gocheva
et al., 2006) and mammary (Sevenich et al., 2010; Vasiljeva
et al., 2008) carcinoma, whereas CtsC deletion has no effect in
these tumors (Gocheva et al., 2006; Ruffell et al., 2013), but
promotes squamous cell carcinoma in the K14-HPV16 model
(Ruffell et al., 2013). Further, cancer cell-derived CtsL is tumor-
promoting in the Rip1-Tag2 (RT2) PanNET model (Gocheva
et al., 2006), whereas it is tumor-suppressive in skin cancer (Be-
navides et al., 2012; Dennema¨rker et al., 2010). Combined dele-
tion of multiple cathepsin family members has also revealed
complex stage-dependent effects on different tumorigenic phe-
notypes (Akkari et al., 2016). For example, simultaneous deletion
of CtsB and CtsS in RT2 mice results in an additive reduction in
angiogenic switching of early preneoplastic lesions, while in end-
stage tumors, several impaired tumorigenic traits are surprisingly
reversed (Akkari et al., 2016). Interestingly, CtsZ was identified
as the protease that functionally compensates for the com-
bined loss of CtsB and CtsS, indicating the selective pressure
in the tumor microenvironment to recalibrate an operational
protease web.
Together, these findings suggest that cathepsins are a well-
connected functional hub controlling multiple signaling path-
ways and that the balance between these downstream effectors
in different tissues and cancer models determines the functional
outcome of cathepsin activity in any specific context. Thus, com-
parison and understanding of contributions from individual
members of the cathepsin family calls for a common experi-
mental model as well as application of a systems-wide approach
for unbiased identification of possible substrates present in the
most relevant in vivo context where all upstream and down-
stream effectors are expressed by specific cells at biologically
relevant concentrations.
Here, we focused on understanding the contributions of ca-
thepsins to tumor progression using the RT2 PanNET mouse
model. RT2 mice express the SV40 large T antigen (Tag) onco-
gene in insulin-producing b-cells, which drives the progressive
multi-step development of multiple pancreatic islet tumors (Ha-
nahan, 1985). RT2 tumors overexpress six cathepsins (B, C, H,
L, S, and Z), broad pharmacological inhibition of which results
in reduced tumor growth, invasion, and angiogenesis (Joyce
et al., 2004). Interestingly, functional genetic studies indicate
that cathepsin C is non-essential for tumor growth and invasion
(Gocheva et al., 2006), whereas the remaining five upregulated
familymembers (B, H, L, S, and Z) have distinct tumor-promoting
effects in the RT2 model (Akkari et al., 2016, 2014; Gocheva
et al., 2010, 2006) (Figure S1A). A cell-adhesion protein E-cad-
herin has been identified as a specific substrate of cathepsins
B, L and S, but not cathepsin C, thus partially explaining the
observed differences in tumor invasion (Gocheva et al., 2006).
Of note, these cathepsins differ mechanistically with CtsH beingboth an amino- and an endopeptidase, CtsB a carboxy- and an
endopeptidase, CtsL and CtsS endopeptidases, and CtsZ a
carboxypeptidase, suggesting that they likely cleave different
proteins and at varying sites, yet affect convergent functional
pathways in vivo. However, the identity of most proteolytic sub-
strates and potential global changes within the proteome or
among other protease classes remain unknown.
To fill this knowledge gap, we employed 8-plex iTRAQ with a
specialized proteomics technique: terminal amine isotopic label-
ing of substrates (TAILS) (Kleifeld et al., 2011, 2010), to identify
pancreatic cancer substrates of cathepsins B, H, L, S, and Z
by comparing knockout (KO) and wild-type (WT) tumors in simul-
taneous 8-plexmass spectrometry analyses.We identified 1,935
proteins and 783 N termini, with the levels of 139 N termini being
significantly changed in one (55% of affected N termini) or
several knockouts, consistent with unique phenotypes observed
for specific genotypes. The majority (56%–83% for different ca-
thepsins) of affected N termini was decreased in tumors from the
knockout animals and thus likely represent lysosomal catabolic
activity of cathepsins. However, a significant amount of affected
N termini (17%–44%) represented stable proteolytic products,
which were enriched for extracellular proteins and are there-
fore candidates for modifying the tumor microenvironment
and potentially mediating signaling roles of cathepsins in
carcinogenesis.
RESULTS AND DISCUSSION
Experimental Design
Pancreatic tumors from 24 individual RT2 mice were analyzed
and included three sets of biological replicates. To quantify
global proteome changes and proteolytic events in RT2 pancre-
atic tumors we used 8-plex iTRAQ labeling, where 8 different
samples collected from six different cathepsin KOs and two
WT RT2 mice were assessed simultaneously in one analysis
minimizing variability from handling and mass spectrometry. To
refine proteome coverage, soluble and organelle proteins were
analyzed separately for each animal (Figure 1A). TAILS data
were augmented by analyses of the global proteome changes
in parallel shotgun-like proteomics experiments designated as
preTAILS (Table S1).
We selected the 13.5-week time point for all proteomics ana-
lyses as this is end stage in the RT2model, and the time point for
which the different cathepsin KO genotypes showed a significant
reduction in tumor volume compared to WT controls (Akkari
et al., 2016, 2014; Gocheva et al., 2010, 2006) (Figure S1A). To
exclude potential differences between WT and cathepsin KO tu-
mors arising simply as a consequence of comparing large versus
smaller tumors respectively, we purposely focused our prote-
omics on similarly-sized lesions across the different genotypes.
There were no significant differences in tumor burden for the in-
dividual animals between genotypes at 13.5 weeks that were
analyzed by TAILS (Figure S1B). Analysis of independent tumors
from littermate cohorts, with a similar size range to those profiled
herein confirmed that the same differences in apoptosis, prolifer-
ation, vascularization, and invasion were observed when individ-
ual cathepsin knockouts were compared to WT tumors (data not
shown) as we have previously reported (Figure S1A).Cell Reports 16, 1762–1773, August 9, 2016 1763
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N=3 Figure 1. Proteome and TAILS Analysisof Pancreatic RT2 Tumors from Cathepsin
Knockout Mice
(A) Experimental design. Pancreatic tumors from
individual wild-type (WT) n = 2 and cathepsin
knockout (Cts KO) n = 6 RT2 mice were analyzed
by TAILS and preTAILS (shotgun) proteomics
analyses. Tumors from 24 mice (N = 3 sets of
biological replicates from individual mice) were
analyzed in six 8-plex experiments as individual
soluble and organelle protein fractions for each of
the three biological replicates. Numbers of pep-
tides and proteins identified with high confidence
(FDR % 1%) are shown. For peptides and pro-
teins identified in each tumor of each genotype
see also Figure S2 for preTAILS and Figure S3 for
TAILS analyses, and Tables S1, S2, S3, S4, and
S5 for all peptides and proteins identified.
(B) Distribution of N termini (internal versus natu-
ral) and their post-translational modifications
of peptides and proteins identified after N-termi-
nal enrichment including distribution of a-amine
acetylated versus non-acetylated N termini. Met,
methionine; Sig, signal peptide; Trans, transit
peptide; Internal processing, protease generated
neo-N termini.
(C) Methionine aminopeptidase and co-trans-
lational aN-acetylation specificity: 1M.(Ac)P1’,
acetylated or non-acetylated amino acid residue
at position 2 (P1’) after met removal (.); 1M.AcP1’,
acetylated amino acid residue at position 2 (P1’)
after met removal (.); 1AcM.P20, amino acid res-
idue at position 2 (P20) after met acetylation; X(n),
any amino acid preceding or following position 1
or 2; n values are shown in parentheses.
(D) Alternative protein translation start sites
and post-translational aN-acetylation specificity.
Frequency distribution of N-terminal amino acids
in the specified internal protein positions (after
X(n)) among peptides identified by TAILS is shown.
See also Figures S1, S2, S3, S4, and S5 and
Tables S1, S2, S3, S4, and S5.PreTAILS Proteome Analysis of Murine RT2 Pancreatic
Tumors
PreTAILS analyses of 3 biological replicates (i.e., before N-ter-
minal peptide enrichment) yielded 1,626 proteins (iProphet
false discovery rate %1%) from 4,748 peptides (Figure S2A;
Table S2), exceeding by several-fold the number of proteins de-
tected previously in similar iTRAQ experiments with pancreatic
tissue from a rat model of diabetes or from cancer patients (Pan
et al., 2009). TAILS analysis yielded 708 proteins represented1764 Cell Reports 16, 1762–1773, August 9, 2016by 1,114 peptides, including 309 unique
to TAILS protein identifications (Fig-
ure 1A), thus increasing the total number
of identified proteins to 1,935 (Figure 1A;
Table S3). In pre-TAILS, 875 peptides
were quantifiable due to labeled primary
amines in the peptides from lysine resi-
dues and/or protein N-terminal a-amines
(Table S4). 11% (97 proteins) were differ-
entially regulatedR2-fold higher or lowerin WT versus cathepsin knockout tumors indicating cleavage
and degradation, respectively, or altered protein expression (Fig-
ures S2B–S2D).
TAILS Analysis of RT2 Pancreatic Tumors
TAILS identified 1,114 N-terminal peptides in 708 proteins,
including 309 unique proteins that escaped detection by con-
ventional shotgun-like preTAILS analyses (Figures 1A and S3).
This is consistent with our strategy of using TAILS to increase
proteome coverage in diverse proteomes (Eckhard et al., 2015).
From 1,114 peptides, 742 had positional annotation in SwissProt
and TopFIND databases (Fortelny et al., 2015) and represented
436 original N termini as translated or after protein maturation
(59%) and 306 neo-N termini from in vivo proteolysis (41%) (Fig-
ure 1B; Table S5). The high numbers of stable proteolytic prod-
ucts identified is comparable to the 41% of cleaved neo-N
termini reported for murine skin (auf dem Keller et al., 2013).
Identification of substantial numbers of natural N termini allowed
for characterization of in vivo N-terminal processing, such as
specificities of N-terminal methionine excision, acetylation,
and frequencies of pro-, transit, and signal peptide removal (Fig-
ures 1B–1D).
Determination of iTRAQ Ratio Cutoffs for Substrate
Discovery
Identification of substrates in in vivo systems is a physiologically
and pathologically relevant approach to deciphering biological
functions of proteases. However, it is complicated by the very
dynamic and interactive nature of tissues where processing
events can be masked by clearance or further degradation of
cleavage products, altered substrate expression levels, and
infiltration of immune cells and intact or cleaved proteins from
the circulation that all act to buffer the system to broad effects.
Moreover, the lack of substrate processing in a specific prote-
ase knockout can be compensated for by other proteases in
the protease web at the same or different cleavage sites (For-
telny et al., 2015). Therefore the differences between wild-type
and gene knockouts are often less pronounced than that
observed in static in vitro experimental systems (Rogers and
Overall, 2013). We analyzed the log-distribution of iTRAQ ratios
for original protein N termini identified in the two different WT
samples included within the same 8-plex experiment as these
represent ratio distributions due to biological and experimental
variability alone, i.e., not due to differences in cathepsin activity.
We chose a highly stringent ratio cutoff of five times SD corre-
sponding to iTRAQ ratios of 0.4 (degradation and protein loss)
and 2.5 (increased proteolytic processing of substrates) (Fig-
ures 2 and S4).
In the absence of compensatory buffering one would expect
almost complete overlap between substrates from the double
and the corresponding individual knockouts. However, 16 pro-
teolytic products (35%) identified in CtsB/;CtsS/ tumors
were unique to this genotype, and 18 (39%), 7 (15%), and 5
(11%) of cleavage products are shared with CtsB/, CtsS/
tumors, or in all three, respectively (Figures S4 and S5). Thus,
CtsB apparently compensates in CtsS/ mice and vice versa,
but in the double knockout, lack of both cathepsins resulted in
larger differences compared to WT tumors with more cleaved
neo-N termini reaching the statistical cutoff. Indeed, of the 16
unique high-confidence substrates in CtsB/;CtsS/ tumors
with iTRAQ ratios below 0.4 or above 2.5, 11 had intermediate
iTRAQ ratios <53 SD (i.e., 1.4 R n < 2.5 and 0.4 > n % 0.7) in
the single CtsB/ or CtsS/ tumors. Nonetheless, as we are
investigating an in vivo system even cleavage events identified
from neo-N termini having ratios < 5x SD may be bona fide
substrates (auf dem Keller et al., 2010, 2013), but with more
false positive substrates, these require validation. Overall, ourreported substrate numbers are conservative and represent
minimum numbers, but these substrates are identified with
very high confidence.
Pyruvate kinase M1/M2 (PKM2) is one such protein with inter-
mediate ratios (WT/KO iTRAQ ratios 1.5 and 1.3 in CtsB/ and
CtsS/ tumors, respectively), yet PKM2 was confirmed as a
new substrate for both cathepsins (Figures 3A and 3B). Despite
being more than 370 amino acids apart, both cleavage sites
identified by TAILS are in close structural proximity. Cleavage
at Q16YQ17 appears to be a pre-requisite to access the other-
wise inaccessible Y390YH391 site, which releases the allosteric
fructose bisphosphate binding site (Dombrauckas et al., 2005)
from the protein and favors a tetramer-to-dimer shift as this is
also the region involved in the intersubunit interaction (Filipp,
2013) (Figure 3C). Pyruvate kinase is a rate-limiting enzyme in
the glycolytic pathway and the switch in expression of the M2
isoform in cancer is largely responsible for the Warburg effect.
Thus, lower pyruvate kinase activity correlates with increased
cell proliferation and tumor growth (reviewed in Yang and Lu,
2013). Therefore, PKM2 processing by CtsB and CtsS in WT
tumors could lower PKM2 activity resulting in larger tumors.
This is consistent with significant decreases in tumor volume in
CtsB/, CtsS/ and CtsB/;CtsS/ mice (Figure S1A).
Lack of Complete Substrate Compensation by Different
Cathepsins in RT2 Tumors
By applying the five times the SD ratio cutoffs of 2.5 and 0.4, we
identified 139 cathepsin-affected peptides compared to the con-
trol WT tumors. Interestingly, only one target, haptoglobin, was
decreased in all six knockouts (Figures 2C–2E and S3B). Thema-
jority of products (55%) had altered iTRAQ ratios only in one
knockout, with 28%, 11%, and 6% regulated in 2, 3, and 4
different knockouts, respectively revealing a lack of family-
wide compensation by cathepsins (or other proteases) at a
cleavage site level. Such high apparent substrate fidelity of indi-
vidual cathepsins in vivo is consistent with the pronounced
phenotypic differences between the individual knockout mice
(Figure S1A) and supports a highly regulatory (signaling) role of
these cathepsins in cancer when substrates are processed
rather than degraded. The lack of cleavage products common
to 5 or 6 conditions does not exclude the existence of shared
substrates. Indeed, these would be detected with equal abun-
dance in WT and KO tumors (WT/KO ratio 1) making them
part of the proteolytic baseline of the tissue and thus indistin-
guishable from proteolytic products of other proteases. This
point is illustrated in Figure S5, which shows a low pair-wise
correlation of N termini quantified across different KOs. Correla-
tions > 0 for all analyzed KO pairs suggests that cathepsins
generally drive biological processes in a similar direction and is
also consistent with our phenotypic analyses of these mice
(reviewed in Olson and Joyce, 2015). As expected, the N-termi-
nomes of the individual KO of CtsB or CtsS are both best corre-
lated (i.e., most similar) to the double CtsB/;CtsS/ KO.
Yet phenotypically these mice are dissimilar, suggesting that
changes in proteolysis alone cannot explain the differences in
phenotypes. We observed a similar extent of correlation be-
tween the N-terminomes of CtsB/ with CtsZ/, CtsS/
with CtsL/, and CtsS/ with CtsB/, indicating similaritiesCell Reports 16, 1762–1773, August 9, 2016 1765
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Figure 2. Substrates Identified in Pancreatic Tumors from Cathepsin Knockout RT2 Mice
(A) Determination of iTRAQ ratio cutoffs for identifying high-confidence cathepsin substrates. Stable neo-N-terminal peptides resulting from cleavage of sub-
strates by cathepsins inwild-typemice (i.e., products of proteolytic processing) are represented byWT/KO iTRAQ ratios >1. Destabilizing cleavages of substrates
by cathepsins in WT tumors (i.e., degradation) result in WT/KO iTRAQ ratios <1. Log-distribution of iTRAQ ratios for original protein N termini identified for tumor
samples from twoWTmice. Five times the SDwas chosen as the significant difference cutoff for quantifiable peptides. The corresponding iTRAQ ratios%0.4 and
R2.5 reflect degradation or proteolytic processing by cathepsins, respectively.
(B–D) Distribution of iTRAQ ratios for the peptides affected in specific KO tumors. In (B) a total of 139 affected N-terminal peptides that exhibited WT/KO iTRAQ
ratios n% 0.4 (white bars) or nR 2.5 (black bars) were analyzed. The total number of peptides (and the corresponding number of proteins in parentheses) with
iTRAQ ratios %0.4 and R2.5 from specific KO tumors is indicated. Numbers of different cathepsin substrates identified with ratios %0.4 (C) and R2.5 (D) in
specific KO tumors are shown.
(E) Percent N-terminal peptides identified with iTRAQ ratios%0.4 (degradation) andR2.5 (processing) in single cathepsin KO tumors (the double KOs were not
considered in this analysis).
(F) Positional distribution of 139 N-terminal peptides within the corresponding proteins in specific KO tumors.
See also Table S7.in the substrate repertoires, either due to direct activity of these
cathepsins or downstream proteases.
As evident from the numbers of affected peptides and their
corresponding proteins in each KO, most of the protein sub-
strates were identified by only one fragment in each KO. CtsH1766 Cell Reports 16, 1762–1773, August 9, 2016had the most targets (70 cleavage sites in 66 proteins) and
CtsL and CtsS the least (31 in 29 proteins, and 27 in 26 proteins,
respectively) (Figure 2B).The majority of peptides had low iTRAQ
ratios reflecting loss of the substrate in the WT tumors, consis-
tent with the classical ascribed role of cathepsins in lysosomal
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Figure 3. Processing of the Metabolic
Regulator, Pyruvate Kinase M2, by Cathep-
sins B and S in RT2 Tumors
(A) Peptides identified by TAILS in pyruvate kinase
M2 (PKM2). WT/KO iTRAQ ratios are listed below.
(B) SDS-PAGE gel (10%) of cleavage assays of
PKM2 by cathepsins. Red arrowheads indicate
cleavage products.
(C) Structural modeling of PKM2 processing by
cathepsins. PKM2 exists as an inactive monomer
(not shown), an active tetramer and a less active
dimer. Two cleavage sites were identified in close
structural proximity (11 A˚), where cleavage at
Q16YQ17 (blue) appeared as prerequisite for the
subsequent cleavage at the otherwise not surface
accessible Y390YH391 site (red). Stars show
location of these two cleavage sites at the hub of
the tetramer. Even though cleavage of the PKM2
dimer seems favorable due to easier access,
cleavage of tetrameric PKM2 cannot be excluded
and is indicated by the diagonal arrow. Cleavage
at Y390YH391 isolates the fructose bisphosphate
(FBP)-binding domains from a truncated PKM2-
dimer. Processing of PKM2 by CtsB and CtsS is
predicted to eliminate allosteric activation by
fructose bisphophate and to disrupt subunit in-
teractions, resulting in a switch from higher activity
tetramers to less active PKM2 dimers. The dimeric
form of PKM2, which is preferentially localized to
the nucleus, may further promote the Warburg
effect by regulating gene transcription.
See also Figure S1.protein degradation. Thus, the aminopeptidase and endopepti-
dase CtsH exhibited the highest levels of degrading activity
with 83% of peptides having iTRAQ ratios %0.4, followed by
the carboxypeptidase CtsZ (74%) and the endopeptidase and
carboxypeptidase CtsB (71%). As discussed, high iTRAQ ratios
represent stable products that result from processing rather than
degradation. Interestingly, CtsS substrates were distributed
almost evenly between the products with high (44%) and low
(56%) iTRAQ ratios and thus reflect an unexpected and relatively
high contribution of CtsS to proteolytic signaling rather than
degradation. Although the processing identified could occur in
endolysosomes it is consistent with an earlier finding of highest
stability and enzymatic activity of this protease under less
acidic conditions outside of the endolysosomal compartment
compared to other cysteine cathepsins (Biniossek et al., 2011;
Repnik et al., 2015). Even though a mechanism for CtsS cytosol
escape was not examined this provides a plausible mechanistic
explanation for the observed high processing activity of CtsS in
RT2 tumors.Cell ReThe majority of peptide targets across
the different knockouts was neo-N termini
or mature N termini after pro/signal/
transit peptide removal with a significant
fraction being original N termini with or
without the initiator methionine (10%–
30%) (Figure 2F). As altered iTRAQ ratios
can also result from changes in proteinlevels, these peptides either represent proteins where expres-
sion levels were affected by the deletion of specific cathepsins
or instances wheremore of the protein was degraded to comple-
tion in the WT tumors and not those of the cathepsin KO (for
N termini having iTRAQ ratios%0.4).
Biological Pathways under Cathepsin Regulation in RT2
Tumors
Gene ontology (GO) analysis of the proteins with altered abun-
dance showed a significant enrichment for the ‘‘extracellular
compartment’’ category among both the up- and downregulated
targets (Figure S3C), consistent with atypical extracellular local-
ization of cathepsins in patient tumor samples and animal cancer
models (Olson and Joyce, 2015). GO analysis of proteins up- or
downregulated by cathepsins capable of endoproteinase versus
exopeptidase activity (CtsB/, CtsS/, CtsB/; Cts/,
CtsL/ versus CtsH/, CtsZ/ mice, respectively) shared
enrichment of extracellular proteins among processed sub-
strates (Figure S3C). Extracellular proteins were also enrichedports 16, 1762–1773, August 9, 2016 1767
Figure 4. Processing of a Nuclear Oncopro-
tein and Apoptosis Inhibitor, Prothymosin
Alpha, in RT2 Tumors
(A) Peptide identified by TAILS in prothymosin
alpha (PTMA). TAILS WT/KO iTRAQ ratios are lis-
ted below. Elevated WT/CtsL/ and WT/CtsH/
ratios identify PTMA as a substrate of nuclear CtsL
and/or a substrate of secreted CtsL and CtsH.
(B) In vitro processing of PTMA by increasing
concentrations of CtsL is shown by SDS-PAGE
(15%).
(C) Loss of nuclear localization signal (NLS) due
to the processing of PTMA by CtsL is pre-
dicted to redistribute PTMA to the cytoplasm in-
hibiting Apaf-1-controlled caspase-9 activation
and decreasing apoptosis in WT RT2 tumors (left
side). Lack of PTMA processing in CtsL/ RT2
tumors is predicted to favor a nuclear distribution
of PTMA, relief of Apaf-1 inhibition, and effective
caspase-9 activation leading to apoptosis in
CtsL/ RT2 tumors (right side).
(D) Effect of the loss of CtsL activity on the cas-
pase-9 protease web in RT2 tumors. All termini
with a ratio <0.4 or >2.5 were selected and used as
input for the TopFIND WebApp PathFINDer using
caspase-9 as a starting point. Proteins with termini
with WT/CtsL/ ratios <0.4 are shown in green,
termini with ratios >2.5 in red. Proteins within the
retrieved paths for which termini with unchanged
ratios could be observed are in gray. Cleavages
retrieved from TopFIND are displayed as gray
arrows; those that result in activation via loss of
a propeptide are shown as dark green arrows.
Inhibiting connections are displayed in red.
See also Figure S1.among products of degradation by endoproteinases (Fig-
ure S3C), whereas degradation substrates of exopeptidases
CtsH and CtsZ showed no enrichment of any GO category
(Figure S3C).
Relatively weak enrichment of only a few specific GO cate-
gories reflects fair representation of a diversity of different bio-
logical processes, functions, and locations among cathepsin
targets. Consistent with their established role in peptide/protein
maturation, processed substrates of CtsH and CtsZ showed
modest enrichment of the neuropeptide signaling pathway GO
category (Figure S3C). GO analysis also revealed a slight bias
of CtsB, L, and S toward degradation of proteins involved in ox-
ygen binding (Figure S3C), primarily hemoglobin. To address the
mechanistic role of cathepsins in tumor progression in the RT2
model, we explored several substrates with high iTRAQ ratios,
including those having known functions in apoptosis as the
more likely candidates for mediating proteolytic signaling.
TAILS identified potent in vivo processing of the nuclear onco-
protein prothymosin alpha (PTMA) by CtsL (WT/CstL ratio 4.4;1768 Cell Reports 16, 1762–1773, August 9, 2016Figure 4A), confirmed by efficient pro-
cessing in in vitro assays (Figure 4B).
PTMA is an oncoprotein with a dual func-
tion as it promotes proliferation and
suppresses apoptosis (Letsas and Fran-
gou-Lazaridis, 2006) by (1) regulatinggene expression through interactions with transcriptional pro-
moters or suppressors and (2) interacting with Apaf1 and
preventing nucleotide exchange, thus inhibiting activation of
caspase-9 and blocking apoptosis (Jiang et al., 2003). Cleavage
at Gly77 leads to loss of the bipartile nuclear localization signal
(Manrow et al., 1991) (Figure 4A) that would prevent nuclear
translocation from the cytoplasm. CtsL has been reported to
have a nuclear isoform lacking the signal peptide due to an alter-
native translation start site (Goulet et al., 2004), thus potentially
placing prothymosin alpha and CtsL in the same cellular
compartment. From the PTMA TAILS data, we hypothesize
that processing of PTMA by CtsL in WT tumors results in a shift
from nuclear to cytoplasmic localization which is accompanied
by increased sequestration of Apaf1 and stronger inhibition
of apoptosis (Figure 4C) consistent with the 3.4-fold increase in
apoptosis observed in CtsL/ mice (Figure S1A). Interestingly,
PTMA is cleaved by known mediators of apoptosis: granzyme
B (Figure 4D), caspase-3, and capsase-7 (Evstafieva et al.,
2000; Van Damme et al., 2009) with several cleavages observed
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Figure 5. Processing of a Modulator of
ER-Induced Apoptosis, 78 kDa Glucose-
Regulated Protein, in RT2 Tumors
(A) Peptides identified by TAILS in 78 kDa
Glucose-regulated protein (GRP78). The WT/KO
iTRAQ peptide ratios are listed below. Two
different cleavage fragments had elevated iTRAQ
ratios in WT compared to CtsB/, CtsS/, and
CtsB/;CtsS/ tumors (dark gray boxes),
revealing processing by CtsB and CtsS.
(B) SDS-PAGE gel (10%) analysis of cleavage as-
says of GRP78 by cathepsins. Red arrowheads
indicate cleavage products.
(C) GRP78 peptides identified by preTAILS. No
significant differences between WT and KO tu-
mors were found in these non-N-terminal GRP78
peptides shows similar total protein levels and
hence that the elevated ratios of peptides identi-
fied by TAILS are from processing and not from
basal proteolysis that may have also increased
with a general increase in protein expression.
(D) Quantification of GRP78 cleavage products
in tumors in vivo. Cathepsin-dependent GRP78
processing in RT2 tumors was quantified from
western blot analyses. Student’s t test was used
to determine statistical significance between ge-
notypes, n = 5 tumors per genotype. *p % 0.02.
Errors are SEM.
See also Figures S1 and S6.in the same C-terminal region of this protein. Of note, the same
pathway is also controlled by the aspartic cathepsin CtsD, which
removes the autoinhibitory N-terminal domain of Aven, an Apaf-
1-binding protein (Melzer et al., 2012), causing increased binding
of Aven to Apaf-1 and preventing apoptosome activation. The
in vivo processing of PTMA by CtsL that we identified suggests
an additional regulatory mechanism for apoptosis initiation.
We also identified in vivo processing of an ER chaperone and
modulator of apoptosis, 78-kDa glucose-regulated protein
(GRP78) that we confirmed by in vitro assays (Figures 5A and
5B). Full-length GRP78 binds and inhibits procaspase7 thus
blocking the ER stress-induced Apaf-1-independent death
pathway, where ATP binding is required for the interaction with
procaspase-7 (Luo and Lee, 2013). We identified 4 different frag-
ments of GRP78 (Figures 5A and 5C), two (starting at positions
350 and 478) had ratios1 across all conditions indicating (1) un-
altered expression levels of GRP78 between WT and KO tumors
and (2) cleavage at positions 350 and 478by all cathepsins exam-
inedorother proteases. Intriguingly, theother twocleavageprod-
uctswere differentially affected inCtsB/, CtsS/ andCtsB/;
CtsS/micewith CtsB potentially cleaving at both positions 250
and 419, and CtsS cleaving only at position 419. These results
were confirmed by western blot analysis of cathepsin-deficient
versus WT tumors, which revealed a significant reduction in aCell Re45-kDa cleavage fragment of GRP78
in CtsS/ tumors (Figures 5C, 5D, and
S6). Importantly, cleavage at L418YD419
within the hinge-region precisely sepa-
rates the ATPase and the protein inter-
action domains, whereas cleavage atN249YG250 splits the ATPase domain in half and dismantles
the central nucleotide-binding site (Figure 6).
As ATP binding is required for interaction with procaspase-7
(Rao et al., 2002), CtsB cleavage at 250Gly within the ATP-binding
domain may result in constitutive inhibition of procaspase-7 and
protection from apoptosis. In contrast, cleavage by CtsB and
CtsS at 419Aspmay result in a disconnect in domain communica-
tion, and loss of procaspase-7 binding that leads to induction of
apoptosis. Consistent with this hypothesis, cleavage in the same
region by the subtilase toxin SubAB induces apoptosis (Paton
et al., 2006). A similar degree of change observed for the two
cleavage events in the double CtsB/;CtsS/ KO may explain
the net zero effect on apoptosis in these mice (Akkari et al.,
2016). However, stronger dependence of 250Gly cleavage on
CtsB activity as compared to cleavage at 419Asp is consistent
with the general pro-apoptotic effect observed in CtsB/ mice.
In addition to the identification of extracellular substrates, we
also independently validated processing of a number of intracel-
lular extra-lysosomal targets. Whereas an acidic extracellular tu-
mor microenvironment (Rothberg et al., 2013) is consistent with
the retention of cathepsin activity and subsequent ECM pro-
cessing outside of the cell, the evident cleavage of substrates
in vivo within the neutral pH environment of intact cells revealed
by TAILS is an intriguing and somewhat surprising result.ports 16, 1762–1773, August 9, 2016 1769
Figure 6. Structural Modeling of GRP78 Processing by Cathepsins
(A and B) Two distinct neo-N termini were identified using TAILS; whereas cleavage in the hinge region (L418YD419; depicted in red, A) results in separation of the
ATPase domain of the protein interaction domain, the second cleavage site (N249YG250; depicted in blue, B) is located centrally in the ATPase domain,
dismantling the nucleotide binding site and thus inactivating the enzyme. ADP is shown in yellow as a ball and stickmodel, and calcium is depicted as a red sphere.Cathepsin S, B and L retain efficient, though suboptimal activity
at neutral pH (Repnik et al., 2015) and thus have the potential to
process the identified substrates in vivo, perhaps as a conse-
quence of alternative trafficking routes or post-translational
modifications specifically within tumor cells or in exosomes.
These are interesting and important issues for the field to
address in the future using sophisticated live cell imaging and
other technological advances as they become available.
In conclusion, our 8-plex iTRAQ TAILS and proteomics ana-
lyses are the only comprehensive in vivo dataset of cancer
degradomics comprising multiple knockouts to date. They
reveal a predominant degradative role for cathepsins in RT2
tumors in vivo, in addition to limited yet clear proteolytic process-
ing of a number of substrates. Processing was frequently non-
redundant indicating specific functions for individual cathepsins
and their substrates in carcinogenesis that needs to be consid-
ered for therapeutic targeting of cathepsins in cancer.
EXPERIMENTAL PROCEDURES
Transgenic Mice
The generation and characterization of cathepsin-deficient RT2mice has been
previously reported (Akkari et al., 2016, 2014; Gocheva et al., 2010, 2006). All
animal studies were performed using protocols approved by the Animal Care
Committee at Memorial Sloan Kettering Cancer Center.
Proteome Preparation
Individual RT2 pancreatic tumors%15 mm3 were used. Each sample included
several tumors from one animal only (RT2 mice develop multiple independent1770 Cell Reports 16, 1762–1773, August 9, 2016lesions), and the cumulative tumor burden for each animal analyzed is shown in
Figure S1B. Pancreatic tumors from individual mice were homogenized for
1min using Ultra-Turrax T25 homogenizer (Ika-Labortechnik) in 100 mM
HEPES (pH 8), supplemented with Complete protease inhibitor cocktail
(Roche). Tissue homogenates were centrifuged for 10 min at 14,000 rpm at
4C to separate soluble proteins from the organelles and pelleted membrane
fraction. The supernatant was carefully aspirated and placed on ice. The pel-
lets were resuspended using a minimal volume of 8 M GuHCl and diluted with
100 mM HEPES (pH 8), supplemented with protease inhibitor cocktail. Both
extracellular and cellular protein fractions were cleaned up by 16% ice-cold
TCA precipitation to remove primary amine-containing compounds, followed
by 30 min incubation on ice and 10 min at 14,000 rpm at 4C, and the pellet
was washed with ethanol. Pellets were resuspended in a minimal volume of
8 M GuHCl. A small aliquot was diluted ten times for determination of protein
concentration (Bio-Rad Protein Assay). The volume of each sample was
adjustedwith water, 1MHEPES (pH 8) and 8MGuHCl to achieve final concen-
trations of protein 2–3 mg/ml, 2.5 M GuHCl, and 250 mM HEPES.TAILS Mass Spectrometry
For iTRAQ-TAILS, 0.2–0.45 mg protein was used from each condition. Sam-
ples were denatured, reduced, and alkylated (auf dem Keller et al., 2013; Klei-
feld et al., 2011, 2010; Prudova et al., 2010). Whole-protein iTRAQ labeling
using 8-plex reagents was performed at room temperature for 1 hr using 1:5
protein:iTRAQ ratio (w/w) and 50% DMSO as a solvent, followed by brief
quenching with ammonium bicarbonate. Afterward the individual reactions
were combined at a 1:1 ratio, cleaned up by acetone-methanol precipitation,
digested by trypsin, and N-terminal peptides were enriched using a dendritic
polyglycerol aldehyde polymer (Flintbox, http://www.flintbox.com/public/
project/1948). Pancreatic tumors from 24 individual mice were analyzed as 3
biological replicates. To increase proteome coverage, extracellular and
cellular proteins were analyzed separately for each animal i.e., samples from
individual mice were not pooled. Each 8-plex analysis included samples from
two WT RT2 mice and six different cathepsin KO (Table S1 shows labeling
schemes and protein amounts used). For each 8-plex analysis, the sample
was analyzed before (pre-TAILS) and after N-terminal enrichment (TAILS).
All samples were pre-fractionated offline on a SCX column and eluted using
a high-performance liquid chromatography salt gradient, followed by individ-
ual C18 STAGE-Tip clean up before liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis on a QStar XL Hybrid ESI mass spectrom-
eter (Applied Biosystems, MDS-Sciex) (Prudova et al., 2010).
MS2 Peptide Assignments and iTRAQ Quantification
MS2 scans were searched against the SwissProt database (release 15.13;
taxonomy mouse [16,220 sequences]) by Mascot (v.2.3) (Matrix Science)
and X!Tandem. Searches were performed with the following parameters:
semi-ArgC cleavage specificity with up to two missed cleavages, cysteine
carbamidomethylation, and peptide lysine iTRAQ8plex were set as fixed
modifications, N-terminal iTRAQ8plex, N-terminal acetylation, and methio-
nine oxidation were set as variable modifications. Peptide tolerance
and LC-MS/MS tolerance were both set at 0.4 Da and the scoring
scheme used was ESI-QUAD-TOF. For combining fractions, secondary vali-
dation and iTRAQ reporter ion quantification, the Trans Proteomic Pipeline
(TPP [v4.3] JETSTREAM rev 1, Build 201005211727) was used invoking
PeptideProphet, iProphet, ProteinProphet, and Libra with purity corrections
provided by the manufacturer, respectively. Samples from pre-TAILS ana-
lyses were analyzed by Mascot and validated using PeptideProphet with
default parameters (min pep length = 7, min prob = 0.05); TAILS samples
were searched by Mascot and X!Tandem, validated by PeptideProphet
(min pep length = 7, min prob = 0, ‘‘No NTT model’’) and searches com-
bined by iProphet. Only peptides with an iProphet probability corresponding
to a false discovery rate (FDR)%1% were included in further analyses. Pre-
TAILS samples were also processed by ProteinProphet and proteins filtered
for ProteinProphet probabilities of R0.9 (corresponding to an FDR % 1%;
Tables S2 and S3).
Peptide Annotation and Statistical Analysis
iTRAQ reporter ion raw intensities were quantile normalized, summed for mul-
tiple spectrum to peptide assignments for TAILS with multiple peptides per
protein for pre-TAILS and normalized to the sum of all channels as described
previously (auf dem Keller et al., 2013). To account for inter-experimental vari-
ation, ratios (WT/KO) were calculated intra-experimentally within each TAILS
experiment, and averaged ratios are reported in Tables S4 and S5. To include
amaximumnumber of differential events between genotypes, the union of pro-
teins and N termini from all TAILS experiments (Table S1 shows experimental
design) was included and the number of experiments contributing to averaged
ratios reported. N-terminal peptides were annotated using CLIPPER (auf dem
Keller and Overall, 2012) and TopFIND (Fortelny et al., 2015), and ratio distri-
butions were determined with assistance of Wessa.net (Free Statistics Soft-
ware, Office for Research Development and Education, v.1.1.23-r7, http://
www.wessa.net/). Correlation plots between TAILS WT/KO ratios for pairs of
cathepsins were plotted in R using the ggplot2 package. For network analysis
all termini with a ratio %0.4 orR2.5 were selected and used as input for the
PathFINDer webApp in the TopFIND N termini and cleavage database (For-
telny et al., 2015). The apoptosis protease caspase-9 was chosen as a starting
point and paths were retrieved for the human network with a path length of
four. To match termini to known cleavage sites, we allowed a range of four
amino acids on the non-prime side to account for ragging. Only the best match
was kept.
In Vitro Cleavage Assays
Activation of recombinant cathepsin proteins (R&D Systems) and cleavage
assays were performed as described (Gocheva et al., 2006). Substrate and
cathepsin protein were used in R10:1 molar ratio as determined by active
site titration with E-64. The assays were performed for 1h in 50mM sodium ac-
etate, 5mMDTT, 150mM sodium chloride (pH 5.5), and stopped by addition of
denaturing sample buffer and boiling. Cleavage fragments were separated by
SDS-PAGE (1 mg of protein substrate per lane) and visualized by silver staining
or using StainsAll dye (Sigma) for PTMA.GRP78 Western Blot Analyses of Tumors
Individual RT2 pancreatic tumors%15 mm3 were lysed in RIPA buffer (Pierce)
containing Complete protease inhibitor cocktail (Roche). Tissue homogenates
were centrifuged for 10 min at 14,000 rpm at 4C to separate soluble proteins
from the organelle and membrane pellet. Total protein in the supernatants was
quantified by BCA (Pierce). Proteins (30 mg) were resolved on a 10% Bis-Tris
mini protein gel (Invitrogen) and transfer membranes probed with polyclonal
anti-GRP78 goat antibody (R&D systems) and were revealed by Donkey
anti-goat-HRP secondary (Jackson Immunoresearch) with Enhanced Chemi-
luminescent substrate (ThermoFisher). Western blots were quantified by
area under the curve analysis using the ImageJ gel analysis macro. Student’s
t test was used to determine statistical significance between genotypes.
In Silico Structural Analysis
Murine GRP78 (UniProt: P20029, G29-I577) and murine PKM2 (UniProt:
P52480, I13-P531) were modeled based on the crystal structures of bovine
hsc70 (PDB: 1YUW; 68.3% sequence identity and a GMQE of 0.76) (Jiang
et al., 2005) and human PKM (PDB: 3U2Z; 97.74% sequence identity and a
GMQE of 0.99) (Anastasiou et al., 2012), respectively, using the ExPASy
SWISS-MODEL Web server (Biasini et al., 2014). Molecular graphics figures
were made using the molecular visualization system PyMOL (The PyMOL
Molecular Graphics System [v.1.7.1.3) (Schro¨dinger) (DeLano, 2005).
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